Savan spent the majority of his 15 year career in the Life Sciences industry working with hundreds of public and private corporations as a Healthcare Investment Banker at Citigroup, Deutsche Bank. From Analyst through Managing Director, he led ~40 financing, IPO, and M&A deals, totaling $35+ billion in deal value, and experienced many invaluable business and scientific lessons from his work with clients across the spectrum of drug, diagnostic, and device technologies such as Amgen, Anacor, Boston Scientific, Eli Lilly, Intermune, Map Pharma, Masimo, Medtronic, Omeros, Pacific Biosciences, and many others. While a Vice President at Deutsche Bank, Savan was selected to lead the firm's build-out of its Healthcare business into Asia, leading to IPO's of the two largest healthcare companies in China, Shanghai Pharma and Fosun Pharma. Savan began his career as a Bioengineer at Life Technologies.
Savan graduated with a M.S.E. in Bioengineering from the University of Pennsylvania and a B.S.E. in Bioengineering focused in Computer Science from the University of California at Berkeley.
After many years of academic and professional experience in the healthcare field, a deeply personal experience later in life gave Savan a new perspective into how much healthcare needed to change – his mother was abruptly diagnosed with stage 4b cancer. This compelled Savan to ask “where were all the signs” and “isn't there a better way,” which led to him returning to his Bioengineering roots and founding BioTrillion, Inc.
Sunil brings over 20 years of biotech management and R&D experience, with significant emphasis on dealmaking to enable value creation from innovation. Most recently, he was EVP & CFO of OncoMed Pharmaceuticals (NASDAQ: OMED), a cancer therapeutics company. He is also currently a member of the Board of Directors of Ligand Pharmaceuticals (NASDAQ: LGND). Sunil has also held roles in finance, business development, and marketing, including positions with OncoMed, BiPar, Allos, Connetics, Abgenix, and Gilead. Earlier in his career, he was with McKinsey & Company advising both biotech and high tech companies. Sunil started his career in the lab, including working as an analytical protein chemist with ZymoGenetics. He is passionate about leveraging novel technologies to improve healthcare, with a particular interest in opportunities at the intersection of the revolutions taking place in IT and biotech.
Sunil graduated with a M.S. in Molecular Bioengineering from the University of Washington and a B.S. in Chemistry from the University of California at Berkeley.
Dr. Kumar is a Lillian & Morrie Moss Chair of Excellence Professor in Computer Science at the University of Memphis. His research focuses on using mobile sensors for self-monitoring of health, wellness, and performance. Dr. Kumar's research group has developed computational models to infer human health and behaviors such as stress, conversation, smoking, craving, brushing, flossing, and drug use from wearable sensor data. He leads several large federally-funded multidisciplinary projects in mobile sensor big data funded by NIH, NSF, and IARPA (worth over $40 million). Dr. Kumar is currently Center Director and Lead PI of the NIH Center of Excellence for Mobile Sensor Data-to-Knowledge (MD2K) that involve investigators in computing, engineering, behavioral science, and medicine from 17 universities. In 2010, he was named "Sensor Guru" by the Popular Science magazine as part of their profiling of America's Ten Brilliant Young scientists and is a frequent keynote speaker or presenter at universities, medical schools, federal agencies including at the White House, international conferences, and national meetings of experts.
Dr. Kumar holds a PhD in Computer Science from Ohio State and BS in Computer Science from the globally renowned Indian Institute of Technology (IIT).
Dr. Liebman brings over four decades of experience in Life Sciences from both industry and academia. Among just a few notable positions he has held, include: Chief Scientific Officer at the Chan Soon-Shiong Institute of Molecular Medicine at Windber; Director of Computational Biology and Global Head of Computational Genetics at Roche; Director of Biomedical Informatics and Pharmacogenomics and Director of Bioinformatics Discovery Research at Wyeth; Advisory Board at the American Heart Association; Professor in the Department of Physiology and Biophysics at Mount Sinai School of Medicine; Professor in the Department of Cancer Biology at the University of Pennsylvania; and many others. He has also been an Advisor and Consultant to many private life sciences companies who have gone on to make an impact in the Healthcare industry.
Dr. Liebman completed his Research Fellowship in Physiological Chemistry, Post-Doctorate in Biochemistry, PhD in Biochemistry, and B.S. in Physical Chemistry.
Dr. Su is a seasoned Bioengineer with over 20 years of experience in the medical device and pharmaceutical industry. His expertise includes combinational device and pharmaceutical formulation. Dr. Su spent the majority of his professional career at Biosensors International, where he rose through the ranks to Director of R&D, until the Company’s acquisition. He has extensive experience in taking conceptual R&D ideas to human clinical trial and finally to commercialization. He is inventor/co-inventor of 32 issued worldwide patents and 25 pending patent applications.
Dr. Su holds a Bachelor’s degree in Chemical Engineering, and Master’s and PhD. degrees in Biomedical Engineering.
Dr. Fontanella brings tremendous clinical experience from his years at the prestigious Memorial Sloan Kettering Cancer Center, as both a data science researcher and as Chief Resident in Medical Physics. Throughout his 10+ years of experience in a healthcare environment, he has developed a passion for developing quantitative methods for improving cancer patients’ treatment outcomes. His personal experiences of seeing close family members bravely battling deadly diseases has sparked a deep drive within him to apply his knowledge and experience towards the improvement of healthcare in the US through advanced machine learning techniques.
Dr. Fontanella graduated with a PhD in Biomedical Engineering from Duke University while studying under the mentorship of Mark Dewhirst, a renowned leader in the field of tumor microcirculation and targeted drug delivery. His thesis work involved in vivo observation of vascular radiation-response in tumors using optical techniques. He also holds a Masters degree in Electrical and Computer Engineering, with a focus in Optics, Photonics, and Image Processing.
David has played a role in technology innovation for nearly 20 years, from designing seminal interfaces at Netscape during the formative days of the internet to leading teams designing breakthrough products, tangible and intangible, at the distinguished institution of innovation, Xerox PARC.
David’s approach to product development borrows from systems thinking where understanding how systems work, the cause and effect relationships of its components help explain and predict behavior and, when combined with business objectives, can more reliably help shape ideal outcomes. He’s been lucky enough to work on complex, large-scale problems and find solutions through a pragmatic use of emergent technology balanced by an understanding of real people, their needs, the business landscape, market trends and cultural shifts for a roster of prestigious companies including Applied Biosystems, Cisco, Leica, Novartis, Proctor & Gamble and Thomson Reuters.
David holds multiple degrees across Design, Business, and the Liberal Arts.
Pranav began his career as an investment banker at FBR & Co., where he focused on the financial institutions and real estate verticals. After several years in investment banking, he became a business consulant to technology clients.
Pranav holds degrees in the Liberal Arts from the University of Pennsylvania and UT Austin.
Shira's interests are focused where technology and life sciences intersect. She is passionate about the power that Bio and Technology hold, and the transformative opportunities it creates to solve problems that previously seemed impossible to overcome.
Shira focused her last internship in Computer Vision and is earning her degree in Biomedical Computing at Queen’s University, a leading academic institution in Canada.